Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Argenteuil – page 83

3 430 clinical trials in Argenteuil, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Argenteuil at a glance
3 430
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 430 trials in Argenteuil

Open in trial search

Study of Sodium Thiosulfate Injections for Patients with Ectopic Calcifications or Ossifications from Dermatomyositis, Systemic Sclerosis, or iPPSD2

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Thiosulfate Pentahydrate
  • Sponsor:Centre Hospitalier Et Universitaire De Limoges

Neoplasm

Recruiting

Study of Dostarlimab for Patients with Advanced or Metastatic Non-Colorectal/Non-Endometrial Cancer with dMMR/MSI, Compared to Standard Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Unicancer

HIV infection+1

Recruiting

Study on Reducing HIV-HBV Treatment with Darunavir, Ritonavir, and Lamivudine for Patients with Controlled Co-Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Darunavir
  • Sponsor:Institut National De La Sante Et De La Recherche Medicale

Study on Short vs. Long Antiplatelet Therapy with Aspirin for Adults After TAVI for Symptomatic Aortic Stenosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Centre Hospitalier Universitaire De Caen Normandie

Long-term Safety and Efficacy Study of JR-141 (Pabinafusp Alfa) for Male Patients with Hunter Syndrome (Mucopolysaccharidosis II)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pabinafusp Alfa
  • Sponsor:Jcr Pharmaceuticals Co. Ltd.

Study of LN-145 (Tumor Infiltrating Lymphocytes) in patients with metastatic non-small-cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Iovance Biotherapeutics Inc.

Glioma

Recruiting

Study Comparing Trametinib and Vinblastine for Children and Young Adults with Newly Diagnosed Low-Grade Glioma with Wild-Type BRAF Gene

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Trametinib
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Study on the Effectiveness and Safety of NS-229 for Patients with Eosinophilic Granulomatosis with Polyangiitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methyl-(1-{[6-{[(1S)-1-Cyclopropylethyl]Amino}-2-(Pyrazolo[5,1-B][1,3]Thiazol-7-Yl)-Pyrimidin-4-Yl]Carbonyl}Piperidin-4-Yl)Carbamate-Mono(4-Methylbenzenesulfonate) Monohydrate
  • Sponsor:Ns Pharma Inc.

B-cell lymphoma

Recruiting

Study on Glofitamab and Drug Combination for Children and Young Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Long-Term Safety of Finerenone with ACE Inhibitors or ARBs for Children and Young Adults with Chronic Kidney Disease and Proteinuria

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency Liver Disease and Mild Fibrosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Neoplasm malignant+7

Recruiting

Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Exelixis Inc.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Argenteuil

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on multiple myeloma and various lymphomas, evaluating novel treatment combinations and maintenance therapies. Studies include investigations of follicular lymphoma and chronic lymphocytic leukemia treatments.

  • Multiple Myeloma Therapy Optimization
  • Lymphoma Treatment Advances
  • Novel Drug Combinations

Particular emphasis on improving patient outcomes through targeted therapies and immunological approaches.

02 Immunology and Infectious Diseases

Clinical trials examining treatments for invasive candidiasis and immune system disorders. Research includes studies on immunosuppression prevention and management in intensive care settings.

  • Antifungal Treatments
  • Immune System Modulation
  • Critical Care Interventions

Focus on developing more effective treatments for both acute and chronic immune conditions.

03 Respiratory and Inflammatory Conditions

Studies investigating treatments for asthma and severe respiratory infections, including community-acquired pneumonia. Research includes evaluation of new delivery systems and therapeutic approaches.

  • Asthma Management
  • Pneumonia Treatment
  • Respiratory Drug Delivery

Emphasis on improving treatment outcomes and patient quality of life through innovative therapeutic strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.